Miao He

Miao He

Auto-generated profile, based on publicly available information

Miao He

Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LZLa Zhang
La Zhang
CRCong Ren
Cong Ren
MHMiao He
Miao He
XCXinyu Chen
Xinyu Chen
HLHongqing Liu
Hongqing Liu
NJNing Jiang
Ning Jiang
Mitochondrial crosstalk between tumor cells and components of the tumor microenvironment (TME) is a critical yet underexplored mechanism driving hepatocellular carcinoma (HCC) progression. Here, we demonstrate that in HCC, mitochondria can be transferred from hepatic stellate cells to cancer cells via tunneling nanotubes (TNTs), supplying essential energy for tumor growth. Simultaneously, cancer cells offload damaged mitochondria to macrophages through extracellular vesicles (EVs), facilitating their clearance and promoting tumor development. To disrupt this mitochondrial exchange, we developed a responsive liposomal nanocarrier (L&G@Lipo PPV ) coencapsulating L-778123 and GW4869 to simultaneously inhibit TNT-mediated and vesicle-mediated mitochondrial transfer. This work provides the first comprehensive evidence of mitochondrial transfer dynamics in the TME, with tumor cells as the central hub, and highlights L&G@Lipo PPV as an innovative and effective strategy to block mitochondrial crosstalk. Our findings address critical challenges of drug solubility and delivery, offering a rational approach to reprogram the TME and suppress liver cancer progression.

20 September 2011 in HEREDITAS
Verified
Journal Article
Closed access
MHMiao He
Miao He
ZWZiwei Wang
Ziwei Wang
RNA interference (RNAi) is an important topic of epigenetics research in post-genome period. RNAi works as a post-DNA replication regulator for gene expression, and it is related to the occurrence and development of malignant tumors. The most usual participators of RNAi are MicroRNA (miRNA) and small interference RNA (siRNA). This review summarizes the basic theory of miRNA and siRNA, and provides recent progresses of RNAi research on gastric cancer. RNAi analysis and technique not only act as powerful tools for studying gene function and action mechanism, but also have diagnostic and therapeutic potential in gastric cancer, even in all kinds of tumors.

1 January 2024 in Cancer Control
Verified
Journal Article
Open access
MHMiao He
Miao He
XLXiao-Dong Li
Xiao-Dong Li
ZWZi-Wei Wang
Zi-Wei Wang
HSHao Sun
Hao Sun
JFJing Fan
Jing Fan
Objective: To retrospectively analyze the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) on the progression free survival (PFS) of advanced gastric cancer (GC) and colorectal cancer (CRC). Method: We retrospectively collected all the HIPEC data of GC and CRC in the Chongqing University Cancer Hospital from August 2018 to April 2023. Data were extracted from inpatient records and outpatient examination records. The IBM SPSS statistics 23.0 software was used to analyze the data. We mainly compared the PFS of HIPEC cases with that of non-HIPEC cases (both from our center and from the literature). PFS was analyzed with the Kaplan-Meier method. Log Rank (Mantel Cox), Breslow (Generalized Wilcoxon), and Tarone-Ware were used for univariate analyses. Result: A total of 342 HIPEC cases were analyzed in this study. Stage IV GC and CRC accounted for 48.5% of the total number of cases. Abdominal pain and distension (47.4%) were the most common side effects from HIPEC. Serious complications were rare (1.8%, including bleeding, perforation, obstruction, and death). The PFS and disease-free survival (DFS) of abdominal malignancy treated with HIPEC were significantly associated with the TNM stage, but not HIPEC numbers nor HIPEC drugs. In stage IV HIPEC cases, adding adjuvant chemotherapy after HIPEC resulted in better PFS. In addition, the association between peritoneal carcinomatosis index (PCI) and PFS of stage IV HIPEC cases was close to significant. Compared with the 33 stage IV (with peritoneal metastases) GC cases without HIPEC in our center from the last 15 years, the PFS of the 56 stage Ⅳ GC cases with HIPEC was not improved significantly (median PFS: 6 ± 2.92 months vs 7 ± 1.63 months for with vs without HIPEC in stage IV GC, respectively; P ≥ 0.05). Compared with the 58 stage IV (with peritoneal metastases) CRC cases without HIPEC in our center from the last 15 years, the PFS of the 86 stage IV CRC cases with HIPEC was not improved significantly either (median PFS: 7 ± 1.68 months vs 7 ± 0.62 months for with vs without HIPEC in stage IV CRC, respectively; P ≥ 0.05). When comparing our HIPEC data with the non-HIPEC data reported by other scholars for the PFS of advanced GC and CRC, the negative results were similar. Conclusion: The PFS/DFS of HIPEC cases was associated with the TNM stage, but not with the HIPEC numbers or HIPEC drugs. PCI may be related to the PFS of stage IV HIPEC cases. Adding chemotherapy or targeted therapy after HIPEC may improve the PFS of stage IV cases. HIPEC did not significantly improve the PFS of stage IV GC or CRC cases in our center.

27 July 2024 in Asian Journal of Surgery
Verified
Journal Article
Open access
MHMiao He
Miao He
JFJing Fan
Jing Fan

20 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MHMiao He
Miao He
HMHe Miao
He Miao
XLXiao Dong Li
Xiao Dong Li
HSHao Sun
Hao Sun
JFJing Fan
Jing Fan
KeywordsHIPEC, colorectal cancer, PFS, OS